Previous 10 | Next 10 |
Kansas City Southern (KSU) +16% on $34B bid from Canadian National.Liquid Media Group Ltd. (YVR) +13% on introduction of its NFT Platform.Obalon Therapeutics (OBLN) +11%.22nd Century Group (XXII) +10%.9 Meters Biopharma (NMTR) +8%.Fisker (FSR) +7% as BAC begins coverage with a ...
Piclidenoson in Phase III for Psoriasis & Namodenoson to Enter Pivotal Phase III for Liver Cancer Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammator...
Knoll (KNL) +31% as Herman Miller to buy the company for $1.8B.AnPac Bio-Medical Science (ANPC) +23% as its paid CDA-based test volume surge 130% in Q1.Clean Energy Fuels (CLNE) +21% on signing an agreement with Amazon.Manchester United plc (MANU) +10% on breakaway Super L...
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
Can-Fite BioPharma (CANF) has completed pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3 adenosine receptor (...
Patent applications filed to protect discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small m...
Can-Fite BioPharma ([[CANF]] +0.4%) announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to ~$130M plus double digit royalties on n...
In addition, to date ~$20 million in non-dilutive upfront payment received Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, t...
Can-Fite Biopharma (CANF): FY GAAP EPS of -$0.04 beats by $1.22.Revenue of $0.76M (-62.6% Y/Y) misses by $0.34M.Press Release For further details see: Can-Fite Biopharma EPS beats by $1.22, misses on revenue
$5M cash infusion received in warrant exercises and upfront money from a licensing deal “2020 was a pivotal year for Can-Fite as we demonstrated a robust clinical proof of concept for both Piclidenoson and Namodenoson,” stated Can-Fite CEO Dr. Pnina Fishman...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite has received agreement from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the current pivotal Phase 3 clinical study Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietar...
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IN...